-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Zymeworks, Maintains $32 Price Target

Benzinga·08/26/2026 12:46:48
Listen to the news
Citizens analyst Reni J. Benjamin reiterates Zymeworks (NASDAQ:ZYME) with a Market Outperform and maintains $32 price target.